Defining the optimal pharmacotherapy of non-ST-segment elevation (NSTE) acute coronary syndromes (ACS): a rapidly moving target

Authors
Citation
We. Boden, Defining the optimal pharmacotherapy of non-ST-segment elevation (NSTE) acute coronary syndromes (ACS): a rapidly moving target, CURR OPIN C, 16(6), 2001, pp. 370-374
Citations number
20
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
CURRENT OPINION IN CARDIOLOGY
ISSN journal
0268-4705 → ACNP
Volume
16
Issue
6
Year of publication
2001
Pages
370 - 374
Database
ISI
SICI code
0268-4705(200111)16:6<370:DTOPON>2.0.ZU;2-Z
Abstract
Acute coronary syndromes (ACS) represent a spectrum of disease, including u nstable angina, non ST-elevation myocardial infarction, and ST-elevation my ocardial infarction. In patients with cardiovascular disease, ACS represent s the most common diagnosis for hospital admission, accounting for nearly 1 .5 million hospital admissions in 1999. Similarly, although improvements in medical therapy have resulted in a dramatic decline in mortality from acut e myocardial infarction (MI)over the last four decades, MI remains the most commocause of in-hospital death in industrialized nations. The approach to managing patients with acute coronary syndromes has evolved dramatically over the past decade and, in many respects, represents a rapi dly moving target in light of recent advances in pharmacotherapy and cathet er-based revascularization. A number of recently-published studies, includi ng the TACTICS Trial [1], the ADMIRAL Trial [2], and the TARGET Trial [3], provide novel information about the relative merits of pharmacologic therap y and invasive intervention, A common theme from these studies is that ther e is a growing consensus among cardiologists that combination therapy with these two modalities may actually provide the best clinical outcomes in ACS patients. (C) 2001 Lippincott Williams & Wilkins, Inc.